<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03267329</url>
  </required_header>
  <id_info>
    <org_study_id>YMC023</org_study_id>
    <nct_id>NCT03267329</nct_id>
  </id_info>
  <brief_title>Duowell® vs. Telmisartan Monotherapy in Mild Dyslipidemia Patients With Hypertension</brief_title>
  <official_title>A Randomized, Open, Parallel, Multicenter, Phase 4 Study to Evaluate the Central Aortic Pressure Effect Between Fixed Dose Combination (Duowell® Tab) and Monotherapy of Telmisartan in Mild Dyslipidemia Patients With Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yuhan Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yuhan Corporation</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to evaluate effect and safety on central blood pressure with Duowell compared
      to telmisartan monotherapy in mild dyslipidemia patients with hypertension during 16 weeks.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 2018</start_date>
  <completion_date type="Anticipated">October 2018</completion_date>
  <primary_completion_date type="Anticipated">October 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes from baseline in mean central systolic blood pressure</measure>
    <time_frame>at week 16</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in mean brachial systolic blood pressure</measure>
    <time_frame>at week 4 and at week 16 and at week 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in mean brachial pulse pressure</measure>
    <time_frame>at week 4 and at week 16 and and at week 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from mean brachial diastolic blood pressure</measure>
    <time_frame>at week 4 and at week 16 and at week 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in augmentation index</measure>
    <time_frame>at week 16 and at week 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in carotid femoral pulse wave velocity</measure>
    <time_frame>at week 16 and at week 28</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Changes from baseline in central blood pressure according to the frequency of access in mobile application</measure>
    <time_frame>up to 4 weeks and up to 16 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Drug compliance between over 50% and less 50% of assessment in mobile application</measure>
    <time_frame>at week 4 weeks and at week 16</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Drug compliance between over 50% and less 50% of assessment in mobile application</measure>
    <time_frame>up to 3 months end of study</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Changes from the end of treatment in central systolic blood pressure after 3 months</measure>
    <time_frame>at 3 months from the end of study</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Numbers of inconvenience reported by mobile application at each visit</measure>
    <time_frame>up to 16 weeks</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">158</enrollment>
  <condition>Hypertension</condition>
  <condition>Dyslipidemia</condition>
  <arm_group>
    <arm_group_label>Duowell® Tab.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Once daily during 16 wks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Telmisartan</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Once daily during 16 wks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Duowell®</intervention_name>
    <description>telmisartan 80mg/rosuvastatin 10mg for ASCVD risk=5%~7.5% or telmisartan 80mg/rosuvastatin 20mg for ASCVD risk≥7.5%</description>
    <arm_group_label>Duowell® Tab.</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Telmisartan</intervention_name>
    <description>telmisartan 80mg</description>
    <arm_group_label>Telmisartan</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria (All of the followings)

          -  40 to 75 years old diagnosed with hypertension

          -  at screening, SBP ≥ 140 mmHg

          -  at randomization, 130 mmHg ≤ SBP ≤160 mmHg or 80 mmHg ≤ DBP ≤ 100 mmHg

          -  at screening, ASCVD risk ≥ 5 %

          -  Those who did not take the dyslipidemic medications during screening or who stopped
             medication for more than 2 months

          -  at screening, 130 mg/dL ≤ Calculated (or Measured) Serum LDL-C ≤ 190 mg/dL

          -  Pregnancy test negative and and who has agreed to perform effective contraception
             during the clinical trial

        Exclusion Criteria (Any of the followings)

          -  known hypersensitivity to AT-1 receptor blockers or statins

          -  Those who are treated with secondary hypertension during screening

          -  Those who are being treated for malignant hypertension during screening

          -  Those who are taking concurrent medication that may affect blood pressure during
             screening

          -  Those who have been diagnosed with myocardial infarction or unstable angina or stroke
             within the last 6 months at screening

          -  Patients with heart failure NYHA III-IV or Left Ventricular Ejection Fraction &lt;40%
             within the last 6 months at screening

          -  Patients with valve disease with hemodynamically significant (over moderate degree)
             obstructive

          -  Those with known atrial fibrillation or atrioventricular conduction disturbance

          -  Those who show the following numerical values during the screening test

               1. CPK ≥ 3 times the normal upper limit

               2. Serum Creatinine &gt; 3 mg/dL

               3. Serum Potassium &gt; 5.5 mmol/L

               4. ALT or AST ≥ 3 times the upper normal limit

          -  Those with known bilateral renal artery stenosis

          -  Patients who underwent open heart surgery within 4 weeks prior to randomization and
             who had a cardiac surgery plan

          -  Those taking statins within 8 weeks before randomization

          -  Those with severe obstructive, limited or other pulmonary disease history

          -  Those with non-cardiac disease that can significantly shorten the expected life span
             to less than 2 years (eg, severe cancer)

          -  at screening, Anti-HIV Ab, HBsAg, HCV Ab positive
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Hojin Lee</last_name>
    <phone>82 2 828 0548</phone>
    <email>hjlee@yuhan.co.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>The Catholic University of Korea, Bucheon ST. Mary's Hospital</name>
      <address>
        <city>Bucheon-si</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inje University Ilsan PAIK Hospital</name>
      <address>
        <city>Goyang-si</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KangBuk Samsung Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Yonsei University Health System, SEVERANCE HOSPITAL</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University, Bundang Hospital</name>
      <address>
        <city>Sŏngnam</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wonju Severance Christian Hospital</name>
      <address>
        <city>Wŏnju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 28, 2017</study_first_submitted>
  <study_first_submitted_qc>August 28, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 30, 2017</study_first_posted>
  <last_update_submitted>January 10, 2018</last_update_submitted>
  <last_update_submitted_qc>January 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Dyslipidemias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Telmisartan</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

